Nilotinib Mylan (Nilotinib)

Nilotinib is used to target BCR‑ABL–driven leukemias, a molecular pathway central to certain blood cancers.

• Philadelphia chromosome‑positive chronic myeloid leukemia (CML): reduces disease progression and improves long‑term survival.
• Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): contributes to remission when combined with chemotherapy.
• CML in accelerated or blast phase: achieves cytogenetic and molecular responses.

• Nilotinib selectively inhibits the BCR‑ABL tyrosine kinase, a fusion protein generated by the Philadelphia chromosome translocation. By binding to the ATP‑binding site of BCR‑ABL, it blocks downstream signaling pathways that drive uncontrolled proliferation of leukemic cells. The inhibition also affects related kinases such as KIT and PDGFR, enhancing its antileukemic activity while sparing normal hematopoietic cells.

Nilotinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Elevated liver enzymes (ALT, AST): mild to moderate increases.
• Nausea or vomiting: gastrointestinal discomfort.
• Diarrhea: loose stools, often transient.
• Rash or skin irritation: mild dermatologic reactions.

Serious or Rare Side Effects

• Cardiovascular events (e.g., arterial occlusive disease): may lead to serious complications.
• Pancreatitis: inflammation of the pancreas requiring medical attention.
• Severe hypersensitivity reactions: including Stevens‑Johnson syndrome.

When prescribing Nilotinib, clinicians should consider several precautionary measures to ensure patient safety.

• Baseline cardiac assessment: evaluate history of arterial disease before initiating therapy.
• Liver function monitoring: check ALT/AST levels regularly during treatment.
• Electrolyte and glucose checks: monitor for hyperglycemia and electrolyte imbalances.
• Drug interaction review: avoid concomitant use with strong CYP3A4 inhibitors.
• Pregnancy and lactation warning: contraindicated in pregnancy (Category D) and not recommended while breastfeeding.
• Store at ambient temperature below 25°C: keep in original packaging, protect from moisture and light.

Nilotinib interacts with several medicines, influencing its plasma concentration and therapeutic effect.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase Nilotinib exposure and toxicity.
• Antacids containing aluminum or magnesium: reduce absorption if taken simultaneously.
• QT‑prolonging agents (e.g., certain antiarrhythmics): heighten risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower Nilotinib levels, reducing efficacy.
• Warfarin: may require INR monitoring due to potential interaction.
• Statins metabolized by CYP3A4 (e.g., simvastatin): dose adjustment may be needed.